Alnylam's Liver Cancer RNAi Program Enters The Clinic

Alnylam Pharmaceuticals's ALN-VSP RNA interference program has begun clinical trials in patients with advanced liver cancers, the Cambridge-MA.-based biotech said April 3

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet